Prostate Disorders Clinical Trials

None

Mild Hypofractionation using Proton Therapy or IMRT for Low- and Intermediate-Risk Prostate Cancer

This is a study to first establish feasibility of the study and then to register the treatment data of adult patients with a diagnosis of low or intermediate risk of prostate cancer presenting for definitive radiation treatment with either proton radiotherapy or IMRT. We propose to employ a hypofractionated strategy …

Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence

TBD

Phase II randomized controlled trial of stereotactic ablative body radiotherapy (SAbR) with or without neurovascular sparing for erectile function preservation in localized prostate cancer

10.0

The Association Between CBT-I Dose and Innate Immunity in Insomnia and Fatigue in Prostate Cancer Patients

The research study is being conducted secondary and after your completion of the primary study (Effect of Radiation Therapy on Sleepiness and Activity in Prostate and Breast Cancer Patients). The purpose of the current study is to assess the effectiveness of a behavioral treatment for insomnia (also known as Cognitive …

SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 multi-institution randomized prospective clinical trial evaluating the impact of cytoreductive radical prostatectomy combined with best systemic therapy on oncologic and quality of life outcomes in men with newly diagnosed metastatic prostate cancer

This study investigates the effects of adding cytoreductive radical prostatectomy (CRP) to the standard treatment, best systemic therapy (BST), for metastatic prostate cancer (mPCa). CRP removes as much of the cancer as possible (and radical prostatectomy removes only prostate) while BST uses drugs toxic to cancer cells: chemotherapy and androgen …

BRCA Founder OutReach (BFOR) Study

These mutations of BRCA genes are associated with greater risks for several types of cancer, including breast, ovarian, and prostate cancer. BFOR will provide patients, families, and their doctors with better information to make important decisions about their health care.

Study to Evaluate Imaging Feasibility, Safety and Diagnostic Performance Post Dosing of an Intraoperative Fluorescent Imaging Agent for Detection of Metastatic Lymph Nodes Primary Tumors and Tumor Margins in Patients with Solid Tumors

Part 2: Biopsy-confirmed diagnosis of Stage 2 to 4 or higher HNSCC, breast cancer, colorectal cancer, prostate cancer, bladder cancer, ovarian cancer The study intervention is an IV dose of ONM-100, which is an intraoperative fluorescence imaging agent.